Hernia Mesh Device Recalls
Taxotere Hair Loss Lawsuits
Talcum Powder Lawsuits
Metal Hip Lawsuits: Depuy | Stryker | Wright | Other
Personal Injury Lawyer - TheLawfirm.com

Free case review

1-855-464-0808
facebook logo google+ logo twitter logo youtube logo

car-accident-tab-blank

wrongful-death-tab-blank

defective-drugs-tab-blank

defective-hip-tab-blank

elderly-abuse-tab-blank

Free Case Review

blank-spacer

 

XARELTO Internal Bleeding Lawsuit News and Updates

Update on the bellwether Xarelto trial

June 5, 2017
A dramatic trial about the possible ill effects of the blood thinner Xarelto continues in Louisiana. The case hinges on whether plaintiff Sharyn Orr died at 67 from using Xarelto, or from pre-existing medical issues.

In the eyes of the plaintiffs, it was the blood-thinning drug, manufactured by drug-industry titans Janssen Pharmaceuticals and Bayer that caused the brain hemorrhage that killed Orr. Orr had worked as an academic advisor at Tulane University for more than 40 years, and died in 2015.

The plaintiff’s attorney argued in a recent court appearance that, for every million people who take Xarelto in order to lower their blood pressure, 36,000 will have a “major bleeding event,” that 5000 of those people will have a “brain bleed,” and that 2000 of the patients with brain bleeds will die from that condition. Orr died from bleeding in her brain.

The attorney for the plaintiff argued that the manufacturers of Xarelto failed to inform users of the drug that a simple clinical procedure called a “prothrombin time,” or PT, test can inform them if they have an excessive level of Xarelto in their blood. The plaintiff’s case hinges on the fact that the drug manufacturers had, but neglected, a responsibility to inform patients of this critical information.

The plaintiffs’ case recently received a boost from Frank W. Smart, MD, a doctor of cardiology at the Louisiana State University School of Medicine. In court testimony, Smart called Xarelto “the worst” of all of blood-thinning medications known as new oral anticoagulants (NOACs). Smart called Xarelto “worst in class among the NOACs.”

In the eyes of the defense, Orr died from a combination of health problems, including diabetes and hypertension (high blood pressure). The defense’s case rests on the notion that Orr was elderly, and had a number of complicating health conditions, including Type-2 diabetes, high cholesterol, kidney disease, and a history of cardiac difficulties.

The attorney for the defense attorney argued that Xarelto does not cause hemorrhages of the kind from which Orr died. The defense’s case is that the drug’s manufacturers did, in fact, include information about PT tests on the Xarelto label, and that, ultimately, the United States Food and Drug Administration (FDA) was the responsible party.

If you or a loved one have suffered serious medical consequences as a result of taking Xarelto, contact one of the expert attorneys at TheLawFirm.com. The consultation is free, and we’re here to help in any way we can.

Talk with aN Attorney now!

Bad Drug Lawsuit - Xarelto & Internal Bleeding

Xarelto (rivaroxaban) is a drug that was approved by the U.S. Food and Drug Administration (FDA) in July 2011. Xarelto was touted as an improvement over warfarin, an anticoagulant that has been in use for several decades. Unfortunately, since then, the FDA has received a large number of ‘adverse event reports’. This means that in 2012, over 750 serious injuries and deaths were reported. There have likely been many thousands more since.

It is true that any drug can have adverse side effects. There are two major problems with Xarelto, however. First, and most alarming, is that people taking Xarelto may have uncontrollable bleeding. While this is a risk shared by all blood thinners, there is currently no antidote in the event of a serious incident. Warfarin bleeding, by contrast, can be staunched rather quickly via the administration of vitamin K. There are many who believe that Xarelto should not have been released with this important safety measure in place.

Secondly, this problem has been compounded by the marketing of Xarelto. Anyone on a blood thinning agent should have routine monitoring. Because this is unpleasant for patients, the manufacturers of Xarelto have seized upon that and made the ‘NO monitoring’ claim as their #1 selling point.

Some doctors have begun to be concerned about Xarelto. Some patients have had major bleeding incidents. Bayer and Johnson & Johnson are now facing lawsuits. Court documents indicate that these claims accuse the companies of withholding information from consumers and the medical community regarding a lack of an agent to reverse uncontrollable internal bleeding. The plaintiffs in these cases also assert that the benefits associated with Xarelto do not justify its risks.

This website will provide regular medical and legal information regarding Xarelto.

Talk with aN Attorney now!

TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:

Real lawyers, real results!

no recovery, no fee!


SHARE THIS